Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365253 | 0.87 | CHRNB4 (0.39) | SIGMAR1HTR2CCHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL8826016 | 0.83 | NISCH (0.45) | NISCHNPC1RAB9ATSHR | |
| SCHEMBL3116016 | 0.81 | CHRNB4 (0.47) | CHRNB4CHRNA3NISCHKDM4ENOTUM | |
| SCHEMBL1365996 | 0.81 | CYP2A6 (0.48) | CHRNB4CHRNA3ALDH1A1SMN1; SMN2NISCH | |
| SCHEMBL2253193 | 0.80 | MAPK14 (0.38) | SIGMAR1HTR2CALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL1365489 | 0.79 | CHRNB4 (0.46) | CHRNB4CHRNA3ALDH1A1SMN1; SMN2NISCH | |
| SCHEMBL5584837 | 0.79 | NISCH (0.42) | SIGMAR1ALDH1A1SMN1; SMN2NISCHNPC1 | |
| SCHEMBL3121636 | 0.79 | HTR2C (0.53) | HTR2CCHRNB4CHRNA3SMN1; SMN2NPY5R | |
| SCHEMBL5585114 | 0.78 | NISCH (0.37) | SIGMAR1ALDH1A1SMN1; SMN2NISCHNPC1 | |
| SCHEMBL2300553 | 0.77 | KDM4E (0.50) | ALDH1A1SMN1; SMN2PKMNPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41998-E1 | Compositions and methods of treatment of sympathetically maintained pain | Arclon Therapeutics, Inc. (US) | 2010-12-14 | — | — | US | claimed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20090099157-A1 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | claimed |
| WO-2008100621-A2 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | claimed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | claimed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | claimed |
| EP-1196403-B1 | ANTIPSYCHOTIC CYCLIC N-ARALKYL AMINES | SANOFI AVENTIS (FR) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | claimed |
| JP-2003503487-A | — | — | 2003-01-28 | — | — | JP | claimed |
| WO-2001002380-A1 | ANTIPSYCHOTIC CYCLIC N-ARALKYL AMINES | SANOFI-SYNTHELABO (FR) | 2001-01-11 | — | — | WO | claimed |
| US-5789410-A | TREATMENT OF SCHIZOPHRENIA, DEPRESSION, PARKINSON'S DISEASE | NEUROGEN CORPORATION (US) | 1998-08-04 | — | — | US | claimed |
| US-5773616-A | NEUROTROPSYCHOLOGICAL FOR SCHIZOPHRENIA AND ANTIDEPRESSANTS | NEUROGEN CORPORATION (US) | 1998-06-30 | — | — | US | claimed |
| US-5563144-A | SERATONIN ANTAGONISTS FOR TREATMENT OF DISORDERS OF CENTRAL NERVOUS, CARDIOVASCULAR AND GASTROINTESTINAL SYSTEMS | RHONE-POULENC RORER S.A. (FR) | 1996-10-08 | — | — | US | claimed |
| EP-0433149-B1 | Serotonin antagonists, their preparation and pharmaceuticals containing them | RHONE POULENC SANTE (FR) | 1994-02-16 | — | — | EP | claimed |
| US-5130313-A | Central nervous system disorders, cardiovascular disorders or gastrointestinal disorders | RHONE-POULENC SANTE (FR) | 1992-07-14 | — | — | US | claimed |
| US-4999355-A | Antiserotonine agents | RHONE-POULENC (FR) | 1991-03-12 | — | — | US | claimed |
| US-4556656-A | HYPOTENSIVE, ANTIPSYCHOTIC, DIABETIC, AND ANALGESIC AGENTS | THE UPJOHN COMPANY (US) | 1985-12-03 | — | — | US | claimed |
| US-4487774-A | Isochromans | THE UPJOHN COMPANY (US) | 1984-12-11 | — | — | US | claimed |
| US-4006232-A | Therapeutic method of treating cardiac arrhythmias utilizing 3-substituted diphenylhydantoins | MILES LABORATORIES, INC. (US) | 1977-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | DPYD, P2RY1, P2RY2 | SIGMAR1 484/4885HTR2C 1166/4885CHRNB4 1702/4885 |
| US-20090099157-A1 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | CTSS, CTSE, CTSK | SIGMAR1 3426/4885HTR2C 2715/4885CHRNB4 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.